Literature DB >> 1546839

Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies.

B G Higgins1, J R Britton, S Chinn, S Cooper, P G Burney, A E Tattersfield.   

Abstract

Inclusion of a standardized measurement of airway function is important in epidemiologic studies of asthma to facilitate comparison between different studies. Bronchial reactivity is widely used in such studies, but measurement of peak expiratory flow (PEF) variability has a number of potential advantages. We compared PEF variability with methacholine challenge tests in a community population sample. Subjects selected at random (n = 95) and on the basis of having experienced wheeze in the last 12 months (n = 130) performed a challenge test with methacholine to a maximum dose of 12.25 mumol and made serial PEF recordings every 2 h for a week. PEF variability was expressed as mean daily maximum amplitude as a percentage of the mean (amplitude % mean). Increased bronchial reactivity and PEF variability were arbitrarily defined as values above the 10th or below the 90th percentiles in the random sample. A measurement of amplitude % mean was available from all 225 subjects, whereas only 115 (51%) had a measurable PD20 methacholine. PD20 measurements correlated weakly but significantly with amplitude % mean (r = -0.44, p less than 0.001). Increased values of both bronchial reactivity and PEF variability were related to the presence of respiratory symptoms in the week before testing. Asthma was more strongly related to increased bronchial reactivity than to PEF variability. Both measurements showed a strong association with atopy and the intraclass correlation coefficients (ratio of between-subject to total variance) were similar for both.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546839     DOI: 10.1164/ajrccm/145.3.588

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Diurnal variability--time to change asthma guidelines?

Authors:  H Reddel; C Jenkins; A Woolcock
Journal:  BMJ       Date:  1999-07-03

2.  Recommendations for the management of cough in adults.

Authors:  A H Morice; L McGarvey; I Pavord
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

Review 3.  Occupational lung disease. 8. The diagnosis of occupational asthma from serial measurements of lung function at and away from work.

Authors:  P Bright; P S Burge
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

4.  Objective measures and the diagnosis of asthma. We need a simple diagnostic test-but don't yet have one.

Authors:  J Britton; S Lewis
Journal:  BMJ       Date:  1998-07-25

5.  Clinicians should be proactive in testing for asthma.

Authors:  A J Wardlaw; I D Pavord
Journal:  BMJ       Date:  1999-01-23

6.  [Recommendations for implementing bronchial provocation tests with pharmacologic substances. German Society of Pneumology--Scientific "Bronchial Provocation Tests" Study Group].

Authors:  G Klein
Journal:  Med Klin (Munich)       Date:  1997-08-15

7.  Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study.

Authors:  H C Siersted; G Mostgaard; N Hyldebrandt; H S Hansen; J Boldsen; H Oxhøj
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

Review 8.  Asthma outcomes: pulmonary physiology.

Authors:  Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

9.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Authors:  P M A Calverley; A Lee; L Towse; J van Noord; T J Witek; S Kelsen
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

10.  Underdiagnosed asthma in South Australia.

Authors:  R J Adams; D H Wilson; S Appleton; A Taylor; E Dal Grande; C R Chittleborough; R E Ruffin
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.